BRIGHAM AND WOMEN'S, MEDICINE, BOSTON, UNITED STATES OF AMERICA | Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, United States | The Harvard ...
KOL Resume for Rie Maurer
BRIGHAM AND WOMEN'S, MEDICINE, BOSTON, UNITED STATES OF AMERICA
Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, United States
The Harvard Clinical and Translational Science Center, Boston, MA
Rie Maurer: Influence Statistics
|randomised controlled miles||#13|
|renal cystadenomas volume||#13|
|sirolimus autophagy inhibition||#18|
|lowdose carbon monoxide||#61|
Open the FULL List in Excel
Prominent publications by Rie Maurer
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis Results of a Phase I Clinical Trial
[ PUBLICATION ]
BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and well tolerated. Secondary end points included changes in lung function.
METHODS: This 48-week, two-center phase I trial evaluated the safety of escalating oral hydroxychloroquine doses ...
|Known for Lung Function | Autophagy Inhibition | Sirolimus Hydroxychloroquine | Clinical Trial | Lymphangioleiomyomatosis Lam|
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
[ PUBLICATION ]
BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF).
METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice ...
|Known for Pulmonary Fibrosis | Patients Ipf | Carbon Monoxide | 12 Weeks | Dose Inhaled|
Lymphangioleiomyomatosis (LAM) is a multisystem disease associated with progressive pulmonary disease that affects almost exclusively women. LAM is characterised pathologically by proliferation of abnormal smooth muscle-like cells carrying mutations in predominantly the tuberous sclerosis complex (TSC) gene TSC2 and, rarely, in TSC1 . LAM can occur sporadically or in association with TSC. Mutations in the TSC genes lead to activation of the mammalian/mechanistic target of rapamycin ...
|Known for Lymphangioleiomyomatosis Lam | Tsc Genes | Tuberous Sclerosis Complex | Mechanistic Target | Muscle Cells|
Key People For Lymphangioleiomyomatosis Lam
Rie Maurer:Expert Impact
Concepts for whichRie Maurerhas direct influence:Lymphangioleiomyomatosis lam, Sirolimus hydroxychloroquine, Patients ipf, Lam patients, Idiopathic pulmonary fibrosis, Inhaled carbon, Cox2 inhibition, Sirolimus autophagy inhibition.
Rie Maurer:KOL impact
Concepts related to the work of other authors for whichfor which Rie Maurer has influence:Carbon monoxide, Lymphangioleiomyomatosis lam, Idiopathic pulmonary fibrosis, Intestinal transplantation, Pharmacological treatments, Tuberous sclerosis complex, Systemic jia.
Is this your profile? Claim your profile Copy URL Embed Link to your profile